目的 探讨风湿性关节炎应用注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗的疗效分析.方法 收集本院2014年1月至2015年5月入院的80例风湿性关节炎患者随机分为两组,对照组患者采用传统治疗,实验组则加施注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗,比较两组患者总体治疗效果、治疗后4、24周相关临床指标.结果 实验组患者总有效率(97.5％)明显高于对照组(80.0％),两组比较差异有统计学意义(x2=4.507,P＜0.05);实验组患者治疗后4、24周关节疼痛数[(1.75±0.57)、(0.77±0.41)]、关节肿胀数[(1.32±0.44)、(0.49±0.34)]、晨僵时间[(5.77±1.67)min、(3.96±1.01)min]、ESR[(11.72±4.37)mm/h、(10.01±4.13)mm/h]、CRP[(0.40±0.11)mg/dl、(0.27±0.09)mg/dl]、DAS28[(1.88±0.74)、(1.76±0.69)]与HAQ[(1.03±0.48)、(0.72±0.33)]均显著低于对照组,两组比较差异有统计学意义(P＜0.01).结论 风湿性关节炎应用注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗的疗效显著,具有借鉴性.%Objective To investigate the efficacy of recombinant human tumor necrosis factor receptor Ⅱ for injection-antibody fusion protein in the treatment of rheumatoid arthritis.Methods 80 patients with rheumatoid arthritis who were hospitalized from January 2014 to May 2015 were randomly divided into two groups.Control group was treated with conventional therapy,while experimental group was treated with recombinant human tumor necrosis factor receptor Ⅱ for injection-antibody fusion protein on the basis.Compared the overall treatment effect,clinical indicators after 4,24 weeks' treatment of two groups.Results The overall effective rate of experimental group (97.5％) was significantly higher that of control group (80.0％),with statistically significant difference (X2=4.507,P＜0.05).After 4,24 weeks' treatment,the number of joint pain of experimental group were (1.75±0.57),(0.77±0.41),the number of swollen joints were (1.32±0.44),(0.49±0.34),the duration of morning stiffness were (5.77±1.67)min,(3.96±1.01)min,ESR were (11.72±4.37) mm/h,(10.01±4.13) mm/h,CRP were (0.40±0.11) mg/dl,(0.27±0.09) mg/dl,DAS28 were (1.88±0.74),(1.76±0.69),and HAQ were (1.03±0.48),(0.72±0.33),all significantly lower than those of control group,with statistically significant differences (P＜0.01).Conclusion Recombinant human tumor necrosis factor receptor Ⅱ for injection-antibody fusion protein in the treatment of rheumatoid arthritis has significant treatment efficacy,with reference.
展开▼
